Talk to your patients about the REFLECTIONS B3271002 study

Dear Colleague,

I am requesting your assistance in identifying and referring patients to a new clinical research study for HER-2 positive metastatic breast cancer. The REFLECTIONS B3271002 clinical research study will evaluate an investigational medication, called PF-05280014, as a potential biosimilar to Herceptin®* (trastuzumab) in patients with HER-2 positive metastatic breast cancer.

Biosimilars are products that are intended to be highly similar to marketed biologic therapies in structure, efficacy, and safety. They are developed and approved via stringent regulatory pathways. Biosimilars are expected to increase global patient access to therapies for a range of diseases including cancer.

PF-05280014 is being developed as a potential biosimilar to Herceptin® (trastuzumab). Access to trastuzumab is often limited because of the high cost of treatment. The purpose of this clinical research study is to determine whether PF-05280014 has sufficient similarity of efficacy and safety to trastuzumab to justify market approval and provide an alternative to patients for whom trastuzumab treatment is indicated.

Key Eligibility Criteria:

  • Female and at least 18 years old
  • Diagnosed with HER-2 positive metastatic breast cancer
  • No prior systemic therapy for metastatic disease (except endocrine therapy)

If you have any questions about REFLECTIONS B3271002 or would like to make a referral or locate your nearest study site, please visit the study website at Interested patients may also visit the study website for more information at

Thank you for your consideration.


Reginald Ewesuedo, MD
Global Clinical Lead
Pfizer REFLECTIONS B3271002 Study

*Herceptin® is a registered U.S. trademark of Genentech, Inc.